307 related articles for article (PubMed ID: 21769849)
1. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
Spiera RF; Gordon JK; Mersten JN; Magro CM; Mehta M; Wildman HF; Kloiber S; Kirou KA; Lyman S; Crow MK
Ann Rheum Dis; 2011 Jun; 70(6):1003-9. PubMed ID: 21398330
[TBL] [Abstract][Full Text] [Related]
3. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.
Fraticelli P; Gabrielli B; Pomponio G; Valentini G; Bosello S; Riboldi P; Gerosa M; Faggioli P; Giacomelli R; Del Papa N; Gerli R; Lunardi C; Bombardieri S; Malorni W; Corvetta A; Moroncini G; Gabrielli A;
Arthritis Res Ther; 2014 Jul; 16(4):R144. PubMed ID: 25007944
[TBL] [Abstract][Full Text] [Related]
4. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.
Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V
Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156
[TBL] [Abstract][Full Text] [Related]
5. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
Gordon J; Udeh U; Doobay K; Magro C; Wildman H; Davids M; Mersten JN; Huang WT; Lyman S; Crow MK; Spiera RF
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-189-93. PubMed ID: 25152211
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
9. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.
Divekar AA; Khanna D; Abtin F; Maranian P; Saggar R; Saggar R; Furst DE; Singh RR
Clin Immunol; 2011 Dec; 141(3):293-303. PubMed ID: 22015344
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
Mendoza FA; Jiménez SA
Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
[No Abstract] [Full Text] [Related]
11. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.
Assassi S; Wu M; Tan FK; Chang J; Graham TA; Furst DE; Khanna D; Charles J; Ferguson EC; Feghali-Bostwick C; Mayes MD
Arthritis Rheum; 2013 Nov; 65(11):2917-27. PubMed ID: 23897225
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
13. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
[TBL] [Abstract][Full Text] [Related]
15. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial.
Acharya N; Sharma SK; Mishra D; Dhooria S; Dhir V; Jain S
Rheumatol Int; 2020 May; 40(5):703-710. PubMed ID: 32239322
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.
Tamaki Z; Asano Y; Hatano M; Yao A; Kawashima T; Tomita M; Kinugawa K; Nagai R; Sato S
Mod Rheumatol; 2012 Feb; 22(1):94-9. PubMed ID: 21633912
[TBL] [Abstract][Full Text] [Related]
18. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
19. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
20. Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review.
Guo L; Chen XX; Gu YY; Zou HJ; Ye S
Clin Rheumatol; 2012 Sep; 31(9):1395-400. PubMed ID: 22875698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
